Keywords: Dyslipedemia, Cholesterol, CETP inhibitors, Roche, Dalcetrapib, Merck & Co, Anacetrapib, Eli Lilly, Evacetrapib, Decision Resources

Discontinuation of dalcetrapib leaves Merck's anacetrapib as the front-running novel CETP inhibitor for dyslipidemia

Article | 20 September 2012

Print This

The discontinuation of Swiss drug major Roche (ROG: SIX) and Japan Tobacco’s dalcetrapib earlier this year (The Pharma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in